GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Theralase Technologies Inc (TSXV:TLT) » Definitions » Price-to-Owner-Earnings

Theralase Technologies (TSXV:TLT) Price-to-Owner-Earnings : (As of May. 25, 2025)


View and export this data going back to 1996. Start your Free Trial

What is Theralase Technologies Price-to-Owner-Earnings?

As of today (2025-05-25), Theralase Technologies's share price is C$0.17. Theralase Technologies does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Theralase Technologies's Price-to-Owner-Earnings or its related term are showing as below:


TSXV:TLT's Price-to-Owner-Earnings is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 27.955
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2025-05-25), Theralase Technologies's share price is C$0.17. Theralase Technologies's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was C$-0.02. Therefore, Theralase Technologies's PE Ratio (TTM) for today is At Loss.

As of today (2025-05-25), Theralase Technologies's share price is C$0.17. Theralase Technologies's EPS without NRI for the trailing twelve months (TTM) ended in was C$-0.02. Therefore, Theralase Technologies's PE Ratio without NRI for today is At Loss.


Theralase Technologies Price-to-Owner-Earnings Historical Data

The historical data trend for Theralase Technologies's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Theralase Technologies Price-to-Owner-Earnings Chart

Theralase Technologies Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Theralase Technologies Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Theralase Technologies's Price-to-Owner-Earnings

For the Medical Devices subindustry, Theralase Technologies's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Theralase Technologies's Price-to-Owner-Earnings Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Theralase Technologies's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Theralase Technologies's Price-to-Owner-Earnings falls into.


;
;

Theralase Technologies Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Theralase Technologies's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=0.17/-0.02
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Theralase Technologies  (TSXV:TLT) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Theralase Technologies Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Theralase Technologies's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Theralase Technologies Business Description

Traded in Other Exchanges
Address
41 Hollinger Road, Toronto, ON, CAN, M4B 3G4
Theralase Technologies Inc brings CLT to patients and personalized ACT to patients based on individual tissue characteristics. It is two separate reportable operating divisions; the Drug Division and the Device Division. The Drug Division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs), and activates them with proprietary and patent-pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The Device Division designs develops, manufactures, and markets proprietary super-pulsed laser technology indicated and cleared by Health Canada and the Food and Drug Administration (FDA) for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions.
Executives
Matthew Thomas Perraton Director
Roger John Dumoulin-white 10% Security Holder, Director, Senior Officer
Kristina Maria Hachey Senior Officer
Arkady Mandel Senior Officer
Guy John Anderson Director
Shawn Shirazi Senior Officer

Theralase Technologies Headlines

From GuruFocus

Top 5 4th Quarter Trades of Mechanics Bank Trust Department

By GuruFocus Research GuruFocus Editor 01-24-2023

Top 5 4th Quarter Trades of Starfox Financial Services, LLC

By GuruFocus Research GuruFocus Editor 02-08-2023

Top 5 3rd Quarter Trades of Financial Sense Advisors, Inc.

By GuruFocus Research GuruFocus Editor 10-13-2022

Top 5 3rd Quarter Trades of Briaud Financial Planning, Inc

By GuruFocus Research GuruFocus Editor 11-05-2022

Top 5 3rd Quarter Trades of Checchi Capital Advisers, LLC

By GuruFocus Research GuruFocus Editor 11-10-2022

Top 5 3rd Quarter Trades of Barry Investment Advisors, LLC

By GuruFocus Research GuruFocus Editor 10-24-2022

Top 5 3rd Quarter Trades of Louis Moore Bacon

By GuruFocus Research GuruFocus Editor 11-16-2022

Top 5 3rd Quarter Trades of PINNACLE FINANCIAL PARTNERS INC

By GuruFocus Research GuruFocus Editor 10-31-2022

Top 5 2nd Quarter Trades of Pinnacle Wealth Management, LLC

By GuruFocus Research GuruFocus Editor 07-29-2022

Strong Tower Advisory Services Buys 2, Sells 3 in 4th Quarter

By GuruFocus Research GuruFocus Editor 01-21-2023